99 related articles for article (PubMed ID: 17351321)
21. An analysis of persistent symptoms in acid-suppressed patients undergoing impedance-pH monitoring.
Sharma N; Agrawal A; Freeman J; Vela MF; Castell D
Clin Gastroenterol Hepatol; 2008 May; 6(5):521-4. PubMed ID: 18356117
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of three different dosages of esomeprazole in the long-term management of reflux disease: a prospective, randomized study, using the wireless Bravo pH system.
Vasiliadis KV; Viazis N; Vlachogiannakos J; Sgouros SN; Stefanidis G; Archimandritis A; Karamanolis DG
Am J Gastroenterol; 2010 Feb; 105(2):308-13. PubMed ID: 19809412
[TBL] [Abstract][Full Text] [Related]
23. Long-term management of patients with symptoms of gastro-oesophageal reflux disease -- a Norwegian randomised prospective study comparing the effects of esomeprazole and ranitidine treatment strategies on health-related quality of life in a general practitioners setting.
Hansen AN; Bergheim R; Fagertun H; Lund H; Wiklund I; Moum B
Int J Clin Pract; 2006 Jan; 60(1):15-22. PubMed ID: 16409423
[TBL] [Abstract][Full Text] [Related]
24. The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pH.
Junghard O; Hassan-Alin M; Hasselgren G
Eur J Clin Pharmacol; 2002 Oct; 58(7):453-8. PubMed ID: 12389067
[TBL] [Abstract][Full Text] [Related]
25. Patient selection for therapy reduction after long-term daily proton pump inhibitor treatment for gastro-oesophageal reflux disease: trial and error.
van der Velden AW; de Wit NJ; Quartero AO; Grobbee DE; Numans ME
Digestion; 2013; 87(2):85-90. PubMed ID: 23364219
[TBL] [Abstract][Full Text] [Related]
26. Caution about overinterpretation of symptom indexes in reflux monitoring for refractory gastroesophageal reflux disease.
Slaughter JC; Goutte M; Rymer JA; Oranu AC; Schneider JA; Garrett CG; Hagaman D; Vaezi MF
Clin Gastroenterol Hepatol; 2011 Oct; 9(10):868-74. PubMed ID: 21782769
[TBL] [Abstract][Full Text] [Related]
27. Effect of baseline symptom severity on patient-reported outcomes in gastroesophageal reflux disease.
Junghard O; Wiklund IK
Eur J Gastroenterol Hepatol; 2007 Jul; 19(7):555-60. PubMed ID: 17556901
[TBL] [Abstract][Full Text] [Related]
28. Validation of the reflux disease questionnaire for an Italian population of patients with gastroesophageal reflux disease.
Pace F; Scarlata P; Casini V; Sarzi-Puttini P; Porro GB
Eur J Gastroenterol Hepatol; 2008 Mar; 20(3):187-90. PubMed ID: 18301298
[TBL] [Abstract][Full Text] [Related]
29. High-dose esomeprazole for treatment of symptomatic refractory gastroesophageal reflux disease--a prospective pH-metry/impedance-controlled study.
Bajbouj M; Becker V; Phillip V; Wilhelm D; Schmid RM; Meining A
Digestion; 2009; 80(2):112-8. PubMed ID: 19641320
[TBL] [Abstract][Full Text] [Related]
30. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety.
Johnson DA; Benjamin SB; Vakil NB; Goldstein JL; Lamet M; Whipple J; Damico D; Hamelin B
Am J Gastroenterol; 2001 Jan; 96(1):27-34. PubMed ID: 11197282
[TBL] [Abstract][Full Text] [Related]
31. 24 Versus 48-hour bravo pH monitoring.
Chander B; Hanley-Williams N; Deng Y; Sheth A
J Clin Gastroenterol; 2012 Mar; 46(3):197-200. PubMed ID: 21959323
[TBL] [Abstract][Full Text] [Related]
32. Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: 'on' or 'off' proton pump inhibitor?
Hemmink GJ; Bredenoord AJ; Weusten BL; Monkelbaan JF; Timmer R; Smout AJ
Am J Gastroenterol; 2008 Oct; 103(10):2446-53. PubMed ID: 18684197
[TBL] [Abstract][Full Text] [Related]
33. Relationship between symptom response and esophageal pH level on standard dose of esomeprazole treatment for gastroesophageal reflux disease.
Peng S; Xiong LS; Xiao YL; Wang AJ; Lin JK; Hu PJ; Chen MH
Chin Med J (Engl); 2010 Aug; 123(15):2012-7. PubMed ID: 20819534
[TBL] [Abstract][Full Text] [Related]
34. Empiric esomeprazole in the treatment of laryngopharyngeal reflux.
DelGaudio JM; Waring JP
Laryngoscope; 2003 Apr; 113(4):598-601. PubMed ID: 12671413
[TBL] [Abstract][Full Text] [Related]
35. Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy.
Zerbib F; Roman S; Ropert A; des Varannes SB; Pouderoux P; Chaput U; Mion F; Vérin E; Galmiche JP; Sifrim D
Am J Gastroenterol; 2006 Sep; 101(9):1956-63. PubMed ID: 16848801
[TBL] [Abstract][Full Text] [Related]
36. Frequency and clinical implications of supraesophageal and dyspeptic symptoms in gastroesophageal reflux disease.
Mearin F; Ponce J; Ponce M; Balboa A; Gónzalez MA; Zapardiel J
Eur J Gastroenterol Hepatol; 2012 Jun; 24(6):665-74. PubMed ID: 22330237
[TBL] [Abstract][Full Text] [Related]
37. Twenty-four-hour esophageal impedance-pH monitoring in healthy preterm neonates: rate and characteristics of acid, weakly acidic, and weakly alkaline gastroesophageal reflux.
López-Alonso M; Moya MJ; Cabo JA; Ribas J; del Carmen Macías M; Silny J; Sifrim D
Pediatrics; 2006 Aug; 118(2):e299-308. PubMed ID: 16831894
[TBL] [Abstract][Full Text] [Related]
38. Validation of a symptom diary for patients with gastro-oesophageal reflux disease.
Puhan MA; Guyatt GH; Armstrong D; Wiklund I; Fallone CA; Heels-Ansdell D; Degl'Innocenti A; Veldhuyzen van Zanten SJ; Tanser L; Barkun AN; Chiba N; Austin P; El-Dika S; Schünemann HJ
Aliment Pharmacol Ther; 2006 Feb; 23(4):531-41. PubMed ID: 16441474
[TBL] [Abstract][Full Text] [Related]
39. Sustained improvement in symptoms of GERD and antisecretory drug use: 4-year follow-up of the Stretta procedure.
Noar MD; Lotfi-Emran S
Gastrointest Endosc; 2007 Mar; 65(3):367-72. PubMed ID: 17321232
[TBL] [Abstract][Full Text] [Related]
40. Addition of esophageal impedance monitoring to pH monitoring increases the yield of symptom association analysis in patients off PPI therapy.
Bredenoord AJ; Weusten BL; Timmer R; Conchillo JM; Smout AJ
Am J Gastroenterol; 2006 Mar; 101(3):453-9. PubMed ID: 16464226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
